Source link : https://newshealth.biz/health-news/gentler-regimen-for-her2-breast-cancer-gets-good-grades-in-5-year-report/
In the DAPHNe study, patients received neoadjuvant therapy with paclitaxel, trastuzumab, and pertuzumab for 12 weeks — a shorter schedule than that currently recommended by guidelines. A secondary analysis of the trial showed that abbreviated treatment was tied to “excellent” long-term outcomes in patients with stage II to III HER2-positive breast cancer. An ultrasensitive ctDNA […]
The post Gentler Regimen for HER2+ Breast Cancer Gets Good Grades in 5-Year Report first appeared on News Health.
—-
Author : News Health
Publish date : 2026-06-25 20:29:00
Copyright for syndicated content belongs to the linked Source.
—-
1 – 2 – 3 – 4 – 5 – 6 – 7 – 8